【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Next-Generation Biologics Market
1.2 Why Should You Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Next-Generation Biologics
2.1 Brief History of Biological Drug Development
2.1.1 Limitations of Present-Generation Biologics
2.2 The Promise of Next-Generation Biologics
2.2.1 Defining Next-Generation Biologics
2.2.1.1 A Definition of Regenerative Medicine
2.2.1.2 Extending Half-Life: Pegylation and Other Novel Strategies
3. World Next-Generation Biologics Market: Outlook and Forecast 2015-2025
3.1 The Next-Generation Biologics Market 2014
3.1.1 Development of the Next-Generation Biologics Market 2008-2014
3.1.2 Rising Demand for Biological Therapies
3.1.3 Next-Generation Drugs as a Share of the Biologics Market 2014
3.1.4 Main Sectors of the Next-Generation Biologics Market: Antibodies and Regenerative Medicine Lead the Way
3.1.5 Leading Companies in the Next-Generation Biologics Market 2014
3.2 The Next-Generation Biologics Market 2015-2025
3.2.1 Growth Drivers for Biological Drug Revenues 2015-2025
3.2.2 The Next-Generation Biologics Market Forecast 2015-2025
3.2.3 Product Launches in All Sectors to Drive Market Growth 2015-2025
3.2.4 Next-Generation Biologics: Market Restraints 2015-2025
3.2.5 Rising Market Shares for Next-Generation Insulins 2015-2025
4. Leading National Submarkets for Next-Generation Biologics 2015-2025
4.1 Leading National Submarkets for Next-Generation Biologics 2014
4.1.1 National Submarket Forecasts 2015-2025
4.1.2 How Will National Submarket Shares Change to 2025?
4.2 Rising Disease Incidence in Important Markets 2015-2025
4.3 Approval of Next-Generation Biologics in Leading National Submarkets
4.4 The US Will be the Largest Submarket for Next-Generation Biologics 2015-2025
4.4.1 US Submarket Forecast 2015-2025
4.5 Next-Generation Biologics in Japan 2015-2025
4.5.1 National Expertise in Stem Cell Research
4.5.2 Japanese Submarket Forecast 2015-2025
4.6 Next-Generation Biologics in Leading EU Countries 2015-2025
4.6.1 Regenerative Medicine Development in the EU
4.6.2 Market Access for Next-Generation Biologics in the EU
4.6.3 Germany: Submarket Forecast 2015-2025
4.6.4 France: Submarket Forecast 2015-2025
4.6.5 UK: Submarket Forecast 2015-2025
4.6.6 Italy and Spain: Submarket Forecasts 2015-2025
4.7 Next-Generation Biologics in Emerging Markets 2015-2025
4.7.1 Next-Generation Biologics Development in Emerging Countries
4.7.2 Chinese Submarket Forecast 2015-2025
4.7.3 Indian Submarket Forecast 2015-2025
5. Next-Generation Antibodies Submarket Outlooks 2015-2025
5.1 Strategies for Improving Antibody Therapies
5.1.1 Antibody-Drug Conjugates: Targeted Cytotoxic Therapies
5.1.2 Engineering Antibodies for Improved Potency
5.1.3 Bispecific Antibodies
5.2 Next-Generation Antibody Therapy Submarket 2013-2014
5.3 Next-Generation Antibody Therapy Submarket 2015-2025
5.3.1 Strong Revenue Growth for Next-Generation Antibodies 2015-2025
5.3.2 Blockbuster Potential Will Drive Growth to 2025: Kadcyla, Adcetris and Cosentyx
5.3.3 Next-Generation Antibodies: Submarket Restraints 2015-2025
5.4 Antibody-Drug Conjugates (ADC) Submarket 2015-2025
5.4.1 Antibody-Drug Conjugates Submarket Forecast 2015-2025
5.4.1.1 Kadcyla and Adcetris: Revenue Forecast 2015-2025
5.4.2 What Will Drive Growth for ADCs to 2025?
5.4.3 A Long Pipeline of ADCs in Clinical Development
5.4.3.1 CMC544 (Pfizer): NHL Development Halted but Trials in ALL Continue
5.4.3.2 NKTR-102 (Nektar Therapeutics): Phase III for Metastatic Breast Cancer
5.4.3.3 CDX-011: Potential for Accelerated Approval in Breast Cancer
5.5 Engineered Antibodies Submarket 2015-2025
5.5.1 Engineered Antibodies Submarket Forecast 2015-2025
5.5.1.1 Gazyva Will Lead the Submarket in 2025
5.5.2 Portfolio Management to Drive Growth 2015-2025
5.5.3 Engineered Antibodies Pipeline 2015
5.5.3.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
5.6 Bispecific Antibodies Submarket 2015-2025
5.6.1 Bispecific Antibodies Submarket Forecast 2015-2025
5.6.2 Bispecific Antibodies: Submarket Drivers and Restraints 2015-2025
5.6.3 One New Approval and Two Phase II Bispecific Antibodies in 2015
5.6.3.1 Blincyto (Amgen): The Second Approved Bispecific Antibody
6. Antibody Fragments and Novel Antibody-Like Drugs: Commercial Potential 2015-2025
6.1 Next-Generation Antibody Fragments: Beyond Fab Fragments
6.1.1 Antibody-Like Proteins Mimic Antibody Therapies
6.1.2 There Are Advantages to Using Fragments and Novel Scaffolds
6.2 Antibody Fragment and ALP Submarket 2015-2025
6.2.1 Antibody Fragment and ALP Submarket Forecast 2015-2025
6.2.2 Pharma Is Investing Strongly in Antibody Fragments and ALPs
6.2.3 Limited Late-Stage R&D Pipeline to Restrain Growth to 2025
6.3 Outlook for Next-Generation Antibody Fragments 2015-2025
6.3.1 Next-Generation Antibody Fragment Submarket Forecast 2015-2025
6.3.2 One Platform Leads the Pipeline in 2015
6.3.2.1 Three Nanobodies in Development for Rheumatoid Arthritis
6.3.2.2 Caplacizumab (Ablynx): Targeting an Orphan Indication
6.4 The Antibody-Like Protein Submarket 2015-2025
6.4.1 Antibody-Like Protein Submarket Forecast 2015-2025
6.4.2 Four ALPs in Clinical Development in 2014
6.4.2.1 Abicipar Pegol (Allergan/Molecular Partners): Development of the Lead Clinical ALP Delayed
6.5 Will Next-Generation Immunotoxins Change the Market to 2025?
6.5.1 Challenges with First Generation Immunotoxins
6.5.2 Fusion Protein Conjugates: Pipeline 2014
6.5.2.1 Moxetumomab Pasudotox
6.5.3 Humanised Immunotoxins
6.5.3.1 Using Granzyme B in Immunotoxins
6.5.3.2 Immunornases: A Future Development Opportunity for Immunotoxins
7. Next-Generation Insulin Submarket: Outlook 2015-2025
7.1 Strategies for Next-Generation Insulin Development
7.1.1 Reformulating Insulin for Convenient Administration
7.1.1.1 Oral Insulin
7.1.1.2 Inhaled Insulin
7.1.1.3 Exubera: A Failed Attempt at Reformulated Insulin
7.2 Next-Generation Insulin Submarket 2012-2014
7.2.1 Tresiba: Approved in the EU and Japan
7.2.1.1 Tresiba: Revenue Forecast 2015-2025
7.3 Next-Generation Insulin Submarket 2015-2025
7.3.1 Next-Generation Insulin Submarket Forecast 2015-2025
7.3.2 Product Launches in the US and EU Will Drive Submarket Growth 2015-2025
7.3.3 Next-Generation Insulin Submarket Restraints 2015-2025
7.3.3.1 Biosimilar Insulins Will be Available from 2015
7.4 Oral Insulin Submarket 2015-2025
7.4.1 Oral Insulin Submarket Forecast 2015-2025
7.4.2 Oral Insulin: Submarket Drivers and Restraints 2015-2025
7.4.3 A Limited Clinical-Stage Pipeline for Oral Insulin 2014
7.4.3.1 Oramed Pharmaceuticals: Oral Insulin in Phase II
7.4.3.2 Oshadi Icp: Phase II Currently Recruiting
7.4.3.3 IN-105: Biocon Partners with Bristol-Myers Squibb for Development
7.4.3.4 Diabetology: Multiple Deals Signed for Emerging Markets
7.4.3.5 Novo Nordisk: NN-1953
7.5 Ultra-Rapid Acting Insulin Submarket 2015-2025
7.5.1 Ultra-Rapid Acting Insulin Submarket Forecast 2015-2025
7.5.1.1 Will Inhaled Insulins Drive Revenue Growth to 2025?
7.5.2 Other Submarket Drivers and Restraints 2015-2025
7.5.3 Ultra-Rapid Acting Insulin Pipeline 2014
7.5.3.1 FIAsp (Novo Nordisk)
7.5.3.2 Adocia: Eli Lilly Opts to Discontinue Partnership
7.5.3.3 Halozyme Therapeutics
7.5.3.4 Biodel: Multiple Ultra Rapid Acting Candidates
7.5.3.5 Afrezza: Inhaled Insulin Nearing the Market
7.5.3.6 Adagio: A Second-Generation Inhaled Insulin
7.6 Ultra-Long Acting Insulin Submarket 2015-2025
7.6.1 Ultra-Long Acting Insulin Submarket Forecast 2015-2025
7.6.2 Revenue Growth Driven by Uptake of Tresiba
7.6.3 Ultra-Long Acting Insulin Pipeline 2015
7.6.3.1 Toujeo: Sanofi’s Next-Generation Insulin Analogue
7.6.3.2 LY2605541 (Eli Lilly)
7.6.3.3 FT-105 (Flamel Technologies)
7.6.3.4 LAPS-Insulin
8. Next-Generation Developments for Other Recombinant Proteins 2015-2025
8.1 Defining Next-Generation for Other Recombinant Protein Sectors
8.1.1 Next-Generation Interferon Beta: Plegridy Set for Approval in 2014
8.1.1.1 Plegridy: Revenue Forecast 2015-2025
8.1.1.2 Plegridy May Compete with Other Long-Acting Interferon Beta Therapies 2015-2025
8.1.2 Next-Generation G-CSF: Teva Expands its Filgrastim Franchise
8.1.2.1 Other Clinical-Stages Advances in Filgrastim Therapy 2014
8.2 Next-Generation Recombinant Coagulation Factors 2015-2025
8.2.1 Next-Generation Recombinant Coagulation Factors Submarket Forecast 2015-2025
8.2.2 Submarket Drivers and Restraints 2015-2025
8.2.3 Clinical Pipeline for Recombinant Coagulation Factors 2015-2025
8.2.3.1 Fused Factors: Biogen Idec’s Eloctate and Alprolix
8.2.3.2 Baxter’s BAX 855
8.2.3.3 CSL Behring’s rIX-FP: Albumin-Bound Coagulation Factors
8.2.3.4 Bayer’s BAY94-9027
8.2.3.5 Novo Nordisk’s N8-GP for Haemophilia A
8.2.3.6 Novo Nordisk’s N9-GP for Haemophilia B
8.2.4 Gene Therapy as a New Treatment Option for Haemophilia
8.3 Next-Generation Growth Hormones 2015-2025
8.3.1 Next-Generation Growth Hormone Submarket Forecast 2015-2025
8.3.2 Brand Loyalty Will Restrain Uptake of Next-Generation Hormones 2015-2025
8.3.3 Long-Acting Growth Hormones
8.3.3.1 Biopartners/LG Life Sciences: The First Long-Acting Growth Hormone
8.3.3.2 Prolor Biotech/OPKO Health
8.3.3.3 Novo Nordisk: Looking to Extend its Market-Leading Position
8.3.3.4 Versartis: XTEN Technology for Half-Life Extension
8.3.4 Reformulated Growth Hormones: Offering Convenient Dosing for Paediatric Patients
8.3.4.1 Critical Pharmaceuticals: Nasal Delivery of Somatropin
9. Regenerative Medicine: Commercial Outlook 2015-2025
9.1 The Regenerative Medicine Submarket 2012-2014
9.1.1 Defining Regenerative Medicine
9.2 The Regenerative Medicine Submarket: Revenue Projections 2015-2025
9.2.1 Stem Cell and Gene Therapy Launches to Drive Growth 2015-2025
9.3 The Stem Cell Therapies Submarket 2015-2025
9.3.1 Prochymal (Mesoblast) for GvHD
9.3.1.1 The Future for Prochymal: Approval in Crohn’s Disease?
9.3.1.2 A Note on Stem Cell Transplants
9.3.2 Stem Cell Therapies Submarket Forecast 2015-2025
9.3.3 Stem Cell Therapies: Submarket Drivers and Restraints 2015-2025
9.3.3.1 Will iPSCs Prove Effective for Stem Cell Therapy?
9.3.4 Stem Cell Therapies Late-Stage Pipeline 2015
9.3.4.1 Cx601 (TiGenix)
9.3.4.2 Mesoblast: Mesenchymal Stem Cell Therapies
9.3.4.3 Baxter Pharmaceuticals: A Leading Cardiovascular Candidate
9.3.4.4 StemEx (Gamida Cell)
9.4 Outlook for Tissue Engineering 2015-2025
9.4.1 Two Sectors Lead the Market: Wound and Cartilage Repair
9.4.1.1 Apligraf Leads the Wound Repair Submarket
9.4.1.2 Organogenesis Will Market Apligraf and Dermagraft from 2014
9.4.2 Tissue Engineering Submarket Forecast 2015-2025
9.4.3 Tissue Engineering: Submarket Drivers and Restraints 2015-2025
9.4.4 Future Developments in Cartilage Repair: Pipeline 2015
9.4.5 Organ Repair and Engineering: The Next Step in Tissue Engineering?
9.4.5.1 Engineered Skin
9.4.5.2 Engineered Veins
9.4.5.3 Organ Transplant: A Long-Term Tissue Engineering Opportunity
9.5 The Gene Therapies Submarket 2015-2025
9.5.1 Glybera Approved and Set for Launch in the EU
9.5.2 Gene Therapies Submarket: Revenue Projections 2015-2025
9.5.3 Glybera’s Approval to Drive Submarket Growth from 2014
9.5.4 There Are More Than Five Gene Therapies in Late-Stage Development
9.5.4.1 ProstAtak: Gene Therapy for Prostate Cancer
9.5.4.2 TVEC (Amgen)
9.5.4.3 Generx (Cardium Therapeutics)
9.5.4.4 Spark Therapeutics: Established in 2013 for Ophthalmic Gene Therapy
10. Next-Generation Biologics: Industry Trends 2015-2025
10.1 Next-Generation Biologics: Market Strengths 2014
10.2 Next-Generation Biologics: Market Weaknesses 2014
10.3 The Next-Generation Biologics Market: STEP Analysis 2015-2025
10.3.1 Social Factors: Rising Disease Incidence and Demands for Convenience
10.3.1.1 Rising Incidence in Cardiovascular Disease, Cancer and Diabetes
10.3.1.2 Next-Generation Biologic Development in Emerging Markets
10.3.2 Technological Developments 2015-2025
10.3.3 Economic Pressures 2015-2025
10.3.3.1 High Drug Costs and Healthcare Spending
10.3.3.2 Limited Commercial Potential in Emerging Markets?
10.3.4 Political Issues: Regulatory Developments 2015-2025
10.4 Next-Generation Biologics: Development Trends 2015-2025
10.4.1 Improving Patient Convenience
10.4.2 Sustained Release Biologics: Pegylation and Beyond
10.4.3 Therapeutic Focus for Next-Generation Biologics
10.4.4 Next-Generation Biologics as Personalised Medicine
10.5 Manufacturing Challenges and Opportunities for Next-Generation Biologics
10.5.1 Contract Manufacturers Invest to Follow Development Trends
10.6 Commercialising Next-Generation Biologics
10.6.1 Product Lifecycle Management for First Generation Biologics
10.6.2 Proving Benefit in Next-Generation Products
10.6.3 Biosimilars as a Challenger 2015-2025
10.7 Partnering for Next-Generation Biologic Development
10.7.1 The Role of Big Pharma in the Next-Generation Biologics Market
10.7.2 Most Development Platforms Stem from Small Biotechs
11. Research Interviews from Our Survey
11.1 Dr Edwin Moses, CEO, Ablynx
11.1.1 Ablynx
11.1.2 Ablynx’s Pipeline and Nanobody Technology
11.1.3 On Caplacizumab
11.1.4 Challenges with Current Biological Therapies
11.1.5 The Next-Generation Biologics Market, 2015-2025
11.2 Dr Mike Romanos, CEO, Crescendo Biologics
11.2.1 Crescendo Biologics
11.2.2 The Benefits in Antibody Fragment Therapies
11.2.3 Treatment of Inflammation Indications with Antibody Fragments
11.2.4 Crescendo’s Fragment Pipeline
11.2.5 Development and Production Platforms for Antibody Therapies
11.2.6 Crescendo’s Humabody ADCs and Multi-Specific T-Cell Engagers
11.2.7 CB001, A Topical Biologic
11.2.8 The Next-Generation Biologics Market, 2015-2025
11.3 Sorrento Therapeutics Inc. Team: Dr Gunnar Kaufmann; VP of Research, Dr Kouros Motamed; VP, Strategic Alliances and Clinical Communications and George Uy; EVP and CCO
11.3.1 Sorrento Therapeutics Inc.
11.3.2 Sorrento’s Pipeline
11.3.3 Drivers and Restraints for Next-Generation Biologics
11.3.4 The Next-Generation Biologics Market, 2015-2025
11.4 Dr Fredrik Frejd, CSO, Affibody
11.4.1 Affibody
11.4.2 Challenges with Current Biological Therapies
11.4.2.1 Current Half-Life Extension Technologies
11.4.3 The Benefits of Affibodies Over Current Antibody Therapies
11.4.4 Focus on Inflammation and Autoimmune Diseases
11.4.5 Development of SOBI002
11.4.6 Regulatory Challenges with Novel Biologics
12. Conclusions from the Research and Analysis
12.1 The Next-Generation Biologics Market Will Grow Strongly to 2025
12.1.1 Next-Generation Antibody Development Will Lead the Market
12.2 New Treatment Regimens Will Drive Demand for Next-Generation Biologics
12.3 Challenges Remain in Developing and Commercialising Next-Generation Biologics
【レポート販売概要】
■ タイトル：次世代生物製剤の世界市場：抗体、再生医療、抗体断片/ALP、インスリン、組換え型血液凝固因子、成長ホルモン■ 英文：Next-Generation Biologics: R&D, Industry and Market Forecasts 2015-2025
■ 発行日：2015年5月
■ 調査会社：visiongain
■ 商品コード：VGAIN5052608
■ 調査対象地域：グローバル
- 補助人工心臓（VAD）の世界市場：LVAD、BiVAD、RVADAbout VADs VADs are of three types — LVADs, BiVADs, and RVADs — that are used to treat heart failure. VADs help the weakened heart to pump blood for circulation to other body organs. Surgeons implant these mechanical devices as a treatment option for severe heart conditions such as acute or chronic cardiac functional deterioration and heart failure. Technavio’s analysts forecast the global ventric …
- ヘリコプターフライトシミュレーターの世界市場2016-2020About Helicopter Simulator A flight simulator is a device used for training novice pilots by recreating aircraft flight environment. It functions in two modes — initial training for new pilots and recurrent training for existing pilots to retain their qualification. Flight simulators are of two types — FFS and flight simulation training devices (FSTD). A flight simulation covers three areas — airc …
- ソーシャル及び検知システムにおけるビックデータ収集：市場機会と課題2013-2019（Capturing Big Data in Social and Detection Systems: Market Opportunities and Challenges 2013 -2019）Every large corporation collects and maintains a huge amount of data associated with its customers including their preferences, purchases, habits, travels, and other personal information. In addition to the large volume, much of this data is unstructured, making it hard to manage. This so called “Big Data” is a challenge for industry verticals yet also an opportunity. The enormous growth potential …
- 高度教育用金融・HRMソフトウェアの世界市場2016-2020About the Higher Education Financial and HRM Software Market The global higher education financial and HRM software market consists of software solutions that are employed by institutions to improve the decision-making and productivity of employees and management of financial resources. The data collected from the software is further analyzed using analytics applications. The analysis is to ensure …
- 泌尿器科用手術機器の世界市場：内視鏡、内視システム、周辺機器、消耗品、付属品The global urology surgical instruments market is expected to reach USD 11.48 Billion by 2021 from USD 7.74 Billion in 2016, growing at a CAGR of 8.2%. The global urology surgical instruments market is segmented on the basis of product, application, and region. By product, the market is categorized into urology endoscopes, endovision systems, peripheral instruments, and consumables and accessories …
- Forest Oil Corporation社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）Forest Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary Forest Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- ヘリコバクター・ピロリ菌検査の世界市場2015The report presents a detailed analysis of the Helicobacter Pylori diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the H. Pylori definition, epidemiology and etiology of are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals …
- ゼオライトの世界市場：製品別（天然、人工）、用途別（触媒、洗剤ビルダー）、地域別予測Global Zeolite Market to reach USD XXX billion by 2025. Global Zeolite Market valued approximately USD XXX billion in 2016 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2017-2025. Key factors success factors of growing demand for detergents, rising hygiene awareness among consumers, and rising refining output. Furthermore, escalating need for natural p …
- 空港照明の世界市場：滑走路照明、誘導路照明、エプロン照明The airport lighting market is projected to grow from USD 473.7 Million in 2016 to USD 672.2 Million by 2021, at a CAGR of 7.2% from 2016 to 2021. Airport lights are used to indicate directions to the aircraft, during landing, takeoff, and parking. These lights are installed in runways, taxiways, and aprons. The runway lights are generally white, taxiway lights are blue in color, and apron lights …
- Athabasca Oil Corporation：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Athabasca Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Athabasca Oil Corporation Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essentia …
- サルモネラ菌検査の世界市場2015The report presents a detailed analysis of the Salmonella diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Salmonella definition, epidemiology and etiology are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for the following market segments: - Hospitals & …
- Bonavista Energy Corporation：石油・ガスバリューチェーン分析レポート2013Bonavista Energy Corporation Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Bonavista Energy Corporation" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Bonavista Energy Corporation”. The report provides key information relating to oil and gas assets of the company along with its operations across the valu …
- 世界のウェアラブル医療技術市場動向（2012-2016）TechNavio's analysts forecast the Global Wearable Medical Technology market to grow at a CAGR of 49.94 percent over the period 2012-2016. One of the key factors contributing to this market growth is the technological innovations. The Global Wearable Medical Technology market has also been witnessing increasing strategic agreements among vendors. However, the instances of product recalls could pose …
- 自動車用軽量材料の世界市場：金属（高張力鋼、アルミニウム）、複合材料、プラスチックAutomotive lightweight materials are used in structure, powertrain, interior, exterior, and other vehicle applications. The global automotive lightweight materials market, by application, has recorded significant growth over the past few years. This growth is estimated to continue in the foreseeable future due to emission reduction regulations. The high consumption rate of lightweight materials in …
- アルミダイカスト機械の世界市場2016-2020About the Aluminum Die Casting Machinery Market The aluminum die casting machinery is used to produce cast aluminum parts for applications in various end-user sectors, namely automotive, aerospace and defense, marine, telecommunications, and others, such as electronic appliances and renewable energy sectors. Aluminum cast parts offer several benefits over other types of nonferrous metals: • The us …
